Antibiotice Ia (ATB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Antibiotice Ia (ATB) has a cash flow conversion efficiency ratio of -0.042x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RON-39.31 Million ≈ $-9.03 Million USD) by net assets (RON944.64 Million ≈ $216.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View ATB stock price for real-time trading data and today's change.
Antibiotice Ia - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Antibiotice Ia's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see ATB stock market capitalisation for the company's overall valuation and market capitalisation.
Antibiotice Ia Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Antibiotice Ia ranked by their cash flow conversion efficiency. Also see Antibiotice Ia asset portfolio for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Legato Merger Corp. IV
NASDAQ:LEGO
|
N/A |
|
Chongqing New Dazheng Property Grp
SHE:002968
|
0.030x |
|
Huida Sanitary Ware Co Ltd
SHG:603385
|
0.038x |
|
Republic Digital Acquisition Company Class A Ordinary Shares
NASDAQ:RDAG
|
0.000x |
|
CapMan Oyj B
HE:CAPMAN
|
0.066x |
|
HD Renewable Energy Co. Ltd.
TW:6873
|
0.070x |
|
Hynar Water Group Co. Ltd.
SHE:300961
|
N/A |
|
Sinopower Semiconductor
TWO:6435
|
0.079x |
Annual Cash Flow Conversion Efficiency for Antibiotice Ia (2022–2025)
The table below shows the annual cash flow conversion efficiency of Antibiotice Ia from 2022 to 2025. Review ATB FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | RON932.07 Million ≈ $214.02 Million |
RON72.44 Million ≈ $16.63 Million |
0.078x | -26.95% |
| 2024-09-30 | RON894.31 Million ≈ $205.35 Million |
RON95.15 Million ≈ $21.85 Million |
0.106x | -26.42% |
| 2023-09-30 | RON846.96 Million ≈ $194.48 Million |
RON122.46 Million ≈ $28.12 Million |
0.145x | -19.82% |
| 2022-09-30 | RON641.43 Million ≈ $147.28 Million |
RON115.66 Million ≈ $26.56 Million |
0.180x | -- |
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system prepar… Read more